Results 191 to 200 of about 33,317 (303)

The evolving role of OMICS in gastrointestinal tumor biology and clinical practice. [PDF]

open access: yesMol Cancer
Li Q   +8 more
europepmc   +1 more source

Gastric Mucosal Molecular Alterations and Multimodal Field‐Based Risk Models for Gastric Cancer Development

open access: yesCancer Science, EarlyView.
DNA methylation in non‐neoplastic background gastric mucosa reflects cumulative inflammatory and exposure‐related field changes before cancer develops. Combining methylation with clinical, endoscopic, histological, and emerging multimodal information may refine calibrated gastric cancer risk prediction and support risk‐adapted personalized endoscopic ...
Genki Usui, Atsushi Kaneda
wiley   +1 more source

Clinical Implications and Research Progress of Salivary Biomarkers for Endocrine and Metabolic Disorders

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Similar to blood, saliva contains a broad range of biomarkers and may offer a non‐invasive, repeatable specimen for endocrine and metabolic assessment. This review aims to synthesise and evaluate recent advances in the clinical translation of salivary biomarkers, while providing a critical assessment of the diagnostic reliability and ...
Chuyan Yu   +7 more
wiley   +1 more source

Impact of OMICS Technologies in Our Understanding of the Pathogenesis of Peri-Implantitis. [PDF]

open access: yesClin Exp Dent Res
Asa'ad F   +6 more
europepmc   +1 more source

Minimal Residual Disease as a Biological Trait: Rethinking Disease Persistence in Hematologic Malignancies

open access: yesEuropean Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) has emerged as a central biomarker in hematologic malignancies, enabling highly sensitive detection of tumor persistence beyond conventional morphologic assessment and serving as an increasingly important surrogate endpoint in clinical trials.
Santino Caserta   +14 more
wiley   +1 more source

Understanding and addressing resistance to IMiDs immunomodulatory compounds in multiple myeloma

open access: yesThe FEBS Journal, EarlyView.
IMiDs are pivotal in the treatment of multiple myeloma. Mechanisms of resistance comprise cell intrinsic and extrinsic pathways, involving tumour microenvironment, immune cell dysfunction, CRBN‐dependent and independent genetic drivers and epigenetic changes.
Maria‐Cynthia Fuentes‐Lacouture   +3 more
wiley   +1 more source

S-adenosylmethionine as an epigenetic treatment of depression in adults with childhood trauma. [PDF]

open access: yesEpigenomics
Alkema A   +12 more
europepmc   +1 more source

Immunophenotypic assessment of pure embryonal carcinoma and yolk sac tumour suggests that reprogramming to non‐seminoma occurs outside the spermatogonial niche

open access: yesHistopathology, EarlyView.
Immunohistochemical analysis of transcription factors in GCNIS associated with pure EC and YST suggests that reprogramming to non‐seminoma occurs outside the spermatogonial niche. In these tumors, reprogramming may occur immediately upon invasion of the stroma or within seminiferous tubules but outside the spermatogonial niche (i.e., in intratubular ...
Daisy Maharjan   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy